To test our hypothesis that therapeutic targeting of oncogenic HRAS could be a clinically relevant choice for the patient, we used subcutaneous BC159-T#3 PDX, which recapitulated the patient tumor with respect to tumor cell morphology, the expression of HRASQ61R protein, and basal squamous subtype (Fig. 2a). The gene discussed is HRAS; the disease is neoplasm.